TABLE 6.
Overall survival and progression‐free survival based on PSMA expression
| Tumour | Features | Function |
PSMA (+) Total/censored |
PSMA (−) Total/censored |
Total Total/censored |
P‐value Log‐rank/Breslow |
|---|---|---|---|---|---|---|
| Primary lung carcinomas | Vascular | OS | 27/3 | 28/4 | 55/7 | .09/.05 |
| PFS | 27/18 | 28/16 | 55/34 | .88/.80 | ||
| Tumour cells | OS | 36/4 | 19/3 | 55/7 | .58/.33 | |
| PFS | 36/23 | 19/11 | 55/34 | .83/.79 | ||
| Lung BMs | Vascular | OS | 36/8 | 20/1 | 56/9 | .03/.01 |
| PFS | 36/23 | 20/11 | 56/34 | .26/.24 | ||
| Tumour cells | OS | 44/9 | 12/0 | 56/9 | .13/.03 | |
| PFS | 44/26 | 12/8 | 56/34 | .84/.67 |
Abbreviations: BMs, brain metastases; OS, overall survival; PFS, progression‐free survival; PSMA, prostate‐specific membrane antigen.